Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2010. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically detailing changes in share interests arising from dividend reinvestment.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present is the transaction price of £12.21 per Ordinary share for the specific share purchases noted below.
Material Changes
On February 4, 2010, the following individuals purchased Ordinary shares through the reinvestment of dividends within an Individual Savings Account (ISA):
- Mr A P Witty: 15 shares
- Mr J S Heslop: 8 shares
- Mr S M Bicknell: 53 shares
- Mr E J Gray: 7 shares
- Mr D S Redfern: 7 shares
The Company and the named persons were advised of this information on February 5, 2010.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory disclosure of director share transactions in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the total number of shares held by each director following this transaction to assess overall ownership concentration.
- Confirm the current market price of GSK shares relative to the £12.21 reinvestment price to evaluate the timing of the transaction.
- Review subsequent filings to determine if these transactions were part of a broader insider trading pattern or standard dividend reinvestment plans.